Clinical Trials
49 trialsA Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Hutchmed
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
FIGHT-209
Incyte Corporation
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
Alaunos Therapeutics
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Jazz Pharmaceuticals
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
BMX-HGG
BioMimetix JV, LLC
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Regeneron Pharmaceuticals
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Servier
Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma
Amgen
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
Basilea Pharmaceutica
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Celgene
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Istari Oncology, Inc.
BrTK02
Candel Therapeutics, Inc.
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
Exelixis
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Novartis
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
Sumitomo Pharma America, Inc.
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc.
PVSRIPO
Istari Oncology, Inc.
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Eisai Inc.
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVAX Biomedical
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVAX Biomedical
PIVOT IO 020
Bristol-Myers Squibb
KING
Karyopharm Therapeutics Inc
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Medicenna Therapeutics, Inc.
A Study in Subjects With Recurrent Malignant Glioma
Eisai Inc.
A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGelâ„¢ in Subjects With Recurrent Glioma
Boston Scientific Corporation
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Celgene
FPA008-003
Five Prime Therapeutics, Inc.
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Celgene
A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma
Hoffmann-La Roche
First in Patient Study for PF-06840003 in Malignant Gliomas
Pfizer
BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma
Boehringer Ingelheim
Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma
Diffusion Pharmaceuticals Inc
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
Merck Sharp & Dohme LLC
Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
Merck Sharp & Dohme LLC
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
MedImmune LLC
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Novartis
A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas
Hoffmann-La Roche
Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Merck Sharp & Dohme LLC
SAPPHIRE
Isarna Therapeutics GmbH
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
GE Healthcare
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
VEG102857
GlaxoSmithKline
Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
Pfizer
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Novartis